Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML.

Abstract

BACKGROUND/AIM:

The therapeutic potential of bromodomain and extra-terminal motif (BET) inhibitors in hematological cancers has been well established in preclinical and early-stage clinical trials, although as of yet, no BETtargeting agent has achieved approval. To add insight into potential response to mivebresib (ABBV-075), a broadspectrum BET inhibitor, co-clinical modeling of individual patient biopsies was conducted in the context of a Phase I trial in acute myeloid leukemia (AML).

MATERIALS AND METHODS:

Co-clinical modeling involves taking the patient's biopsy and implanting it in mice with limited passage so that it closely retains the original characteristics of the malignancy and allows comparisons of response between animal model and clinical data. Procedures were developed, initially with neonate NOD/Shi-scid-IL2rγnull (NOG) mice and then optimized with juvenile NOG-EXL as host mice, eventually resulting in a robust rate of engraftment (16 out of 26, 62%).

RESULTS:

Results from the co-clinical AML patient-derived xenograft (PDX) modeling (6 with >60% inhibition of bone marrow blasts) were consistent with the equivalent clinical data from patients receiving mivebresib in monotherapy, and in combination with venetoclax. The modeling system also demonstrated the activity of a novel BD2-selective BET inhibitor (ABBV-744) in the preclinical AML setting. Both agents were also highly effective in inhibiting blast counts in the spleen (10/10 and 5/6 models, respectively).

CONCLUSION:

These findings confirm the validity of the model system in the co-clinical setting, establish highly relevant in vivo models for the discovery of cancer therapy, and indicate the therapeutic value of BET inhibitors for AML and, potentially, myelofibrosis treatment.

• Authors: Daniel H Albert, Neal C Goodwin, Angela M Davies, Jenny Rowe, Gerold Feuer, Michael Boyiadzis, Kathleen A Dorritie, Maria Mancini, Regina Gandour-Edwards, Brian A Jonas, Gautam Borthakur, Ibrahim Aldoss, David A Rizzieri, Olatoyosi Odenike, Thomas Prebet, Sanjana Singh, Relja Popovic, Y U Shen, Keith F McDaniel, Warren M Kati, Dimple A Modi, Monica Motwani, Johannes E Wolff, David J Frost
• Journal: In vivo (Athens, Greece) (In Vivo) 2022 Jul-Aug Vol. 36 Issue 4 Pg. 1615-1627 ISSN: 1791-7549 [Electronic] Greece
• PMID: 35738590 (Publication Type: Journal Article)
• Copyright: Copyright © 2022, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Chemical References

• Pyridones
• Sulfonamides
• mivebresib

Topics

• Animals
• Cell Line, Tumor
• Humans
• Leukemia, Myeloid, Acute (drug therapy, pathology)
• Mice
• Mice, Inbred NOD
• Mice, SCID
• Pyridones (pharmacology, therapeutic use)
• Sulfonamides